Department of Medicine, NTT West Osaka Hospital, Japan.
J Atheroscler Thromb. 2009 Oct;16(5):546-52. doi: 10.5551/jat.992. Epub 2009 Sep 3.
Previous studies have been inconsistent results about the effects of statins on serum triglyceride (TG), high-density lipoprotein cholesterol (HDL-C) and high sensitivity C-reactive protein (hsCRP) levels. We therefore investigated the effects of pitavastatin on serum lipid profiles and hsCRP levels in patients with type 2 diabetes mellitus.
The study population was 65 Japanese type 2 diabetic patients who had been administered 2 mg daily of pitavastatin and completed a 6-month follow-up. Serum lipids and hsCRP were measured before and after treatment for 1, 3, and 6 months.
Total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C) and TG had significantly reduced after 1 month and remained reduced for 6 months, while HDL-C levels had significantly increased after 1 month and remained at the higher level for 6 months. Baseline median levels of hsCRP were 0.49 mg/L and showed a significant reduction to 0.37 mg/L at 6 months' treatment (p<0.001). Six-month changes in hsCRP levels were not associated with those in TC, LDL-C, HDL-C or TG.
Pitavastatin improved serum lipid profiles and reduced serum hsCRP levels in type 2 diabetic patients with relatively low inflammation. The effect on hsCRP was not related to the effects on serum lipid profiles.
先前的研究对于他汀类药物对血清三酰甘油（TG）、高密度脂蛋白胆固醇（HDL-C）和高敏 C 反应蛋白（hsCRP）水平的影响结果并不一致。因此，我们研究了匹伐他汀对 2 型糖尿病患者血脂谱和 hsCRP 水平的影响。
研究对象为 65 名接受每日 2mg 匹伐他汀治疗且完成 6 个月随访的日本 2 型糖尿病患者。在治疗前、治疗 1、3 和 6 个月后检测血清脂质和 hsCRP。
治疗 1 个月后，总胆固醇（TC）、低密度脂蛋白胆固醇（LDL-C）和 TG 显著降低，且持续降低 6 个月，而高密度脂蛋白胆固醇（HDL-C）水平在治疗 1 个月后显著升高，并持续升高 6 个月。hsCRP 的基线中位数水平为 0.49mg/L，治疗 6 个月后降至 0.37mg/L（p<0.001）。hsCRP 水平的 6 个月变化与 TC、LDL-C、HDL-C 或 TG 的变化无关。
匹伐他汀改善了 2 型糖尿病患者的血脂谱，并降低了血清 hsCRP 水平，而炎症水平相对较低。hsCRP 的作用与血清脂质谱的作用无关。
